Putative identification of functional interactions between DNA intercalating agents and topoisomerase II using the V79 in vitro micronucleus assay.
Clastogenicity is frequently observed following treatment of mammalian cells with new chemical entities. This clastogenicity, unless proven otherwise, is assumed to result from the imperfect repair of DNA lesions produced from covalent chemical/DNA interaction. However, clastogenicity can also arise via other mechanisms such as non-covalent chemical intercalation into DNA resulting in poisoning of cellular DNA topoisomerase II (topo II) and stabilization of DNA double strand breaks. We have recently reported modifications to the V79 in vitro micronucleus assay which allow an indirect evaluation of both the intercalative and topoisomerase-interactive activities of chemical agents. In the present studies we have used these modified assays to further assess the validity of this approach in an evaluation of a number of intercalating and non-intercalating polycyclic compounds. It is shown that intercalating agents may be catalytic topo II inhibitors (e.g. chloroquine (CHL), tacrine (TAC), 9-aminoacridine (9AA), ethidium bromide (EB)) or topo II poisons (e.g. proflavine (PROF), auramine O (AUR) and curcumin (CURC)). Still other intercalators are shown to lack detectable topo II-interactions, (e.g. imipramine (IMP), quinacrine (QUIN), 2-aminoanthracene (AA), iminostilbene (IMN) and promethazine (PHE)). It is concluded that (1) the clastogenicity of three agents, PROF (a typical DNA intercalating agent), and AUR and CURC (both structurally atypical intercalating agents, with unknown clastogenic mechanisms), may be due to topo II poisoning; (2) other intercalating agents may either act as catalytic topo II inhibitors or exhibit no functional topo II interaction; (3) The use of these cell-based approaches may provide a logical first step in determining if unexpected clastogenicity associated with test article exposure is due to a topo II interaction.
Snyder
Ronald D
RD
DuPont Pharmaceuticals Company, Stine-Haskell Research Center, P.O. Box 50, H1/1710, Newark, DE 19714, USA. Ronald.snyder@spcorp.com
Arnone
Marc R
MR
D000818:Animals; D000873:Anthracenes / Q000633:toxicity; D002384:Catalysis; D002460:Cell Line; D006224:Cricetinae; D003412:Cricetulus; D007099:Imipramine / Q000633:toxicity; D007364:Intercalating Agents / Q000633:toxicity*; D015162:Micronucleus Tests; D009153:Mutagens / Q000633:toxicity*; D011796:Quinacrine / Q000633:toxicity; D059005:Topoisomerase II Inhibitors
D000873:Anthracenes; D007364:Intercalating Agents; D009153:Mutagens; D059005:Topoisomerase II Inhibitors; C006593:2-anthramine; D011796:Quinacrine; D007099:Imipramine